Vaccine for the prevention of breast cancer recurrence
AssigneeThe Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.
InventorsGeorge Peoples, Sathibalan Ponniah
Life of this patent
Estimating the term…
Abstract
Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.
Claims20
A method of preventing breast cancer recurrence in a subject, wherein the subject is in remission following treatment with a standard course of therapy, comprising administering to the subject a composition in an amount effective to prevent breast cancer recurrence, wherein the composition comprises a pharmaceutically effective carrier, a peptide having the amino acid sequence SEQ ID NO:2, and granulocyte macrophage-colony stimulating factor, and wherein the composition does not contain an E75 peptide having the amino acid sequence of SEQ ID NO:3.
A vaccine composition comprising a pharmaceutically acceptable carrier, an effective amount of a peptide having the amino acid sequence SEQ ID NO:2, and granulocyte macrophage-colony stimulating factor, and wherein the composition does not contain an E75 peptide having the amino acid sequence of SEQ ID NO:3.
Dependencies are inferred from the claim text.